PSA Response and Clinical Outcomes in Prostate Cancer Treatment

Interpreting PSA Response

• The 66% PSA response rate observed in patients receiving Lu-177-PSMA-617 indicates a favorable biochemical response, strongly associated with improved clinical outcomes, including longer progression-free survival, overall survival, and better quality of life, according to the National Comprehensive Cancer Network 1.

Clinical Management Implications

• PSA velocity provides useful information for monitoring treatment response, though PSA is not cancer-specific and can be affected by various factors, as noted by the American College of Physicians 2.
• PSMA PET/CT imaging is superior to conventional imaging for detecting low-volume metastatic disease and should be used for restaging evaluation, as recommended by the American College of Radiology 3.
• The American Society of Clinical Oncology recommends that patients demonstrating a PSA response should continue with the planned treatment regimen, with grade 3-4 adverse events less frequent with Lu-177-PSMA-617 (33%) compared to cabazitaxel (53%), as reported by the National Comprehensive Cancer Network 1.
• The European Association of Urology suggests that do not add concurrent systemic therapies based solely on PSA kinetics if the patient is demonstrating response and tolerating treatment well 3.